Wet AMD Clinical Trials
3 recruiting trials for Wet AMD. Eligibility criteria explained in plain English.
3
Total Trials
3
Recruiting Now
2
Phase 3 Trials
3
Sponsors
Recruiting Trials
RECRUITINGPhase 2 / Phase 3NCT04704921
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in...
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD)....
Sponsor: AbbVieEnrolling: 63020 locations
RECRUITINGPhase 3NCT06856577
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular...
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with...
Sponsor: Adverum Biotechnologies, Inc.Enrolling: 28420 locations
RECRUITINGPhase 3NCT07317934
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
This is a Phase III, randomized, open-label, active-controlled study to evaluate the efficacy and safety of subretinal injection of LX102 in participants with neovascular...
Sponsor: Innostellar Biotherapeutics Co.,LtdEnrolling: 33220 locations